Colorectal Cancer Clinical Trial
Official title:
Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial
The primary objectives of this randomized clinical trial are to evaluate if perioperative SDD can reduce clinical anastomotic leakage rate and its septic consequences as well as other infectious complications. By reduction of septic complications long-term oncological outcome might simultaneously improve.
Rationale:
Infectious complications and especially anastomotic leakage severely impede the recuperation
of patients following colorectal cancer surgery. When the normal gut barrier fails such as in
anastomotic leakage, pathogenic microorganisms like Gram-negative bacteria enter the
circulation and may cause severe sepsis which is associated with considerable mortality.
Moreover, anastomotic leakage has a negative impact on colorectal cancer prognosis. Selective
decontamination of the digestive tract (SDD) is a prophylaxis regimen that employs oral
nonabsorbable antibiotics to eradicate pathogenic micro-organisms like Gram-negative
bacteria.
Objective:
The primary objectives of this randomized clinical trial are to evaluate if perioperative SDD
can reduce clinical anastomotic leakage rate and its septic consequences as well as other
infectious complications. By reduction of septic complications long-term oncological outcome
might simultaneously improve. Secondary objectives are a decline in reoperation rate,
in-hospital mortality, readmission rate, duration of hospital stay and ICU admission,
non-infectious complications, improvement of quality of life and reduction of costs.
Study design:
A randomised multicenter clinical trial comparing perioperative SDD in addition to standard
antibiotic prophylaxis with standard antibiotic prophylaxis alone in patients with colorectal
cancer who undergo elective surgical resection with curative intent.
Study population:
Patients 18 years or older are eligible for inclusion when they are diagnosed with colon or
rectal cancer without signs of distant metastases. Patients may be scheduled for either
laparoscopic or open resection with curative intent, including construction of an anastomosis
(either with or without diverting stoma). Patients are not eligible for inclusion in case of
concomitant metastases or acute obstruction.
Intervention:
Patients are randomly allocated for either perioperative SDD (intervention group) including
standard antibiotic prophylaxis or standard treatment (including standard antibiotic
prophylaxis alone) (control group). The solution containing SDD is orally taken 4 times
daily, starting 3 days before surgery and continued until normal bowel passage or at least 3
days after surgery. Both groups receive a single preoperative intravenous dose of 1000 mg
Cefazoline and 500 mg Metronidazole, which is the current standard antibiotic prophylaxis.
Main study parameters/endpoints:
The main study parameter is anastomotic leakage. The research hypothesis refers to an
estimated decrease in anastomotic leakage rate in the SDD treated group (from 9% to 4%). As
anastomotic leakage has been shown unfavourable forlong term oncological outcome, we presume
an improvement in disease free survival, which serves as important secondary endpoint.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |